Logo image of CLLS

CELLECTIS - ADR (CLLS) Stock Fundamental Analysis

USA - NASDAQ:CLLS - US15117K1034 - ADR

2.84 USD
-0.52 (-15.48%)
Last: 9/29/2025, 4:30:00 PM
3.64 USD
+0.8 (+28.17%)
After Hours: 9/22/2025, 9:36:14 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CLLS. CLLS was compared to 536 industry peers in the Biotechnology industry. CLLS has a bad profitability rating. Also its financial health evaluation is rather negative. CLLS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLLS has reported negative net income.
CLLS had a negative operating cash flow in the past year.
CLLS had negative earnings in each of the past 5 years.
In the past 5 years CLLS reported 4 times negative operating cash flow.
CLLS Yearly Net Income VS EBIT VS OCF VS FCFCLLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -28.30%, CLLS is in the better half of the industry, outperforming 69.03% of the companies in the same industry.
CLLS has a Return On Equity (-103.16%) which is in line with its industry peers.
Industry RankSector Rank
ROA -28.3%
ROE -103.16%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
CLLS Yearly ROA, ROE, ROICCLLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CLLS's Gross Margin of 3.66% is fine compared to the rest of the industry. CLLS outperforms 72.01% of its industry peers.
The Profit Margin and Operating Margin are not available for CLLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLLS Yearly Profit, Operating, Gross MarginsCLLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLLS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CLLS has been increased compared to 5 years ago.
Compared to 1 year ago, CLLS has an improved debt to assets ratio.
CLLS Yearly Shares OutstandingCLLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLLS Yearly Total Debt VS Total AssetsCLLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

CLLS has an Altman-Z score of -0.61. This is a bad value and indicates that CLLS is not financially healthy and even has some risk of bankruptcy.
CLLS has a Altman-Z score (-0.61) which is in line with its industry peers.
CLLS has a Debt/Equity ratio of 0.91. This is a neutral value indicating CLLS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.91, CLLS is not doing good in the industry: 75.56% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Altman-Z -0.61
ROIC/WACCN/A
WACC6.33%
CLLS Yearly LT Debt VS Equity VS FCFCLLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

CLLS has a Current Ratio of 1.38. This is a normal value and indicates that CLLS is financially healthy and should not expect problems in meeting its short term obligations.
CLLS's Current ratio of 1.38 is on the low side compared to the rest of the industry. CLLS is outperformed by 81.90% of its industry peers.
A Quick Ratio of 1.38 indicates that CLLS should not have too much problems paying its short term obligations.
CLLS has a Quick ratio of 1.38. This is amonst the worse of the industry: CLLS underperforms 81.16% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.38
CLLS Yearly Current Assets VS Current LiabilitesCLLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

CLLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.89%, which is quite impressive.
The Revenue has grown by 236.67% in the past year. This is a very strong growth!
The Revenue has been growing by 16.44% on average over the past years. This is quite good.
EPS 1Y (TTM)52.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)236.67%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%91.42%

3.2 Future

CLLS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -56.20% yearly.
CLLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.22% yearly.
EPS Next Y-213.93%
EPS Next 2Y-50.24%
EPS Next 3Y-56.2%
EPS Next 5YN/A
Revenue Next Year-3.47%
Revenue Next 2Y26.88%
Revenue Next 3Y12.87%
Revenue Next 5Y29.22%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLLS Yearly Revenue VS EstimatesCLLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
CLLS Yearly EPS VS EstimatesCLLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLLS Price Earnings VS Forward Price EarningsCLLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLLS Per share dataCLLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as CLLS's earnings are expected to decrease with -56.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-50.24%
EPS Next 3Y-56.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTIS - ADR

NASDAQ:CLLS (9/29/2025, 4:30:00 PM)

After market: 3.64 +0.8 (+28.17%)

2.84

-0.52 (-15.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/dmh
Earnings (Next)11-03 2025-11-03
Inst Owners15.56%
Inst Owner Change-13.52%
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap284.92M
Analysts84.62
Price Target7.36 (159.15%)
Short Float %0.4%
Short Ratio1.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.93%
Min EPS beat(2)4.37%
Max EPS beat(2)25.48%
EPS beat(4)4
Avg EPS beat(4)48.46%
Min EPS beat(4)4.37%
Max EPS beat(4)145.69%
EPS beat(8)7
Avg EPS beat(8)30.86%
EPS beat(12)9
Avg EPS beat(12)22.27%
EPS beat(16)12
Avg EPS beat(16)21.54%
Revenue beat(2)1
Avg Revenue beat(2)21.17%
Min Revenue beat(2)-20.05%
Max Revenue beat(2)62.39%
Revenue beat(4)3
Avg Revenue beat(4)64.94%
Min Revenue beat(4)-20.05%
Max Revenue beat(4)161.56%
Revenue beat(8)5
Avg Revenue beat(8)33.5%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.56%
PT rev (3m)-2.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.22%
EPS NY rev (1m)0%
EPS NY rev (3m)6.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-43.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-40.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.05
P/FCF N/A
P/OCF N/A
P/B 2.93
P/tB 2.97
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.93
BVpS0.97
TBVpS0.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.3%
ROE -103.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.66%
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.04%
Cap/Sales 3.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.38
Quick Ratio 1.38
Altman-Z -0.61
F-Score3
WACC6.33%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y-213.93%
EPS Next 2Y-50.24%
EPS Next 3Y-56.2%
EPS Next 5YN/A
Revenue 1Y (TTM)236.67%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%91.42%
Revenue Next Year-3.47%
Revenue Next 2Y26.88%
Revenue Next 3Y12.87%
Revenue Next 5Y29.22%
EBIT growth 1Y46.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.31%
EBIT Next 3Y-33.24%
EBIT Next 5Y-29.24%
FCF growth 1Y51.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.32%
OCF growth 3YN/A
OCF growth 5YN/A